A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients

2001 ◽  
Vol 21 (9) ◽  
pp. 1251-1260 ◽  
Author(s):  
Saeed Hosseini ◽  
Jeongmin Lee ◽  
Ramon T. Sepulveda ◽  
Peter Rohdewald ◽  
Ronald R. Watson
Keyword(s):  
Blood Pressure ◽  
Crossover Study ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Double Blind Placebo

Clonidine is not a Useful Adjunct to Methadone Gradual Detoxification in Opioid Addiction

1994 ◽  
Vol 165 (3) ◽  
pp. 370-374 ◽  
Author(s):  
Hamid Ghodse ◽  
Judith Myles ◽  
Stephen E. Smith
Keyword(s):  
Blood Pressure ◽  
Clinical Examination ◽  
Drug Dependence ◽  
Controlled Trial ◽  
Double Blind ◽  
Treatment Unit ◽  
Double Blind Placebo ◽  
To Receive ◽  
Drug Dependence Treatment

BackgroundThe role of clonidine in the management of opioid-dependent individuals undergoing gradual detoxification.MethodA double-blind placebo-controlled trial was conducted on 86 voluntary in-patients (59 male, 27 female) aged 18–47 years, at a specialist drug-dependence treatment unit. Patients entered the trial when on 40 mg of methadone daily or less, and were randomised to receive incremental doses of clonidine (increasing from 0.2 mg daily to 1.2 mg daily) during a 14-day period of gradual methadone detoxification and for four weeks thereafter. Blood pressure was monitored and severity of opioid abstinence was assessed by questionnaire and by clinical examination.ResultHalf the subjects were withdrawn or defaulted from the trial by the end of two weeks, those receiving clonidine earlier than those receiving dummy medication (9 of the former and only one of the latter because of systemic hypotension). Similar proportions of subjects completed detoxification in the two groups. In those who completed detoxification, clonidine did not significantly reduce either the symptoms or objective signs of opioid withdrawal.ConclusionsThese findings suggest that clonidine has no place as an adjunct to a programme of gradual opioid detoxification.

The Role of Acetaldehyde in Human Psychomotor Function: A Double-Blind Placebo-Controlled Crossover Study

2010 ◽  
Vol 67 (9) ◽  
pp. 840-845 ◽  
Author(s):  
Sung-Wan Kim ◽  
Kyung-Yeol Bae ◽  
Hee-Young Shin ◽  
Jae-Min Kim ◽  
Il-Seon Shin ◽  
...  
Keyword(s):  
Crossover Study ◽  
Psychomotor Function ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF FOLIC ACID ADJUNCT FOR 8 WEEKS IN HYPERHOMOCYSTEINAEMIC HYPERTENSIVE PATIENTS IN ZARIA, NIGERIA

2018 ◽  
Vol 8 (5) ◽  
pp. 338-348 ◽  
Author(s):  
Obiageli U ONYEMELUKWE ◽  
Bilkisu B MAIHA ◽  
Lydia O AYANWUYI ◽  
Tukur DAHIRU
Keyword(s):  
Blood Pressure ◽  
Folic Acid ◽  
Repeated Measures ◽  
Controlled Study ◽  
Base Line ◽  
Double Blind ◽  
Adjunct Therapy ◽  
Hypertensive Patients ◽  
Double Blind Placebo ◽  
Significant Difference

Objectives: This study was aimed at determining the effect of folic acid adjunct therapy on homocysteine (HCY) and blood pressure (BP) levels in hypertensive subjects. Method: The study was a double blind placebo-controlled trial on 100 hypertensive patients randomised into 50 folate and 50 placebo groups, where the folate group had 5 mg folic acid daily for 8 weeks. Fasting plasma homocysteine, folate and blood pressure levels were determined at baseline, at 4 and at 8 weeks. The Mixed Model Repeated Measures analysis of variance was applied for data analysis. Results: Hyperhomocysteinaemia was found at baseline in the folate (21.3 ± 5.7 µmol/L) and placebo (21.6 ± 4.9 µmol/L) groups which did not differ statistically (p > 0.05). Folic acid adjunct therapy, reduced homocysteine levels at 4 weeks by 2.0 µmol/L (9.2 %, p < 0.05) and at 8 weeks by 1.2 µmol/L (5.6 %, p < 0.05), with no significant (p > 0.05) systolic and diastolic blood pressure lowering effect. High base-line folate levels were found in both folate (113.8 ± 51.2 ng/ml) and placebo groups (109.5 ± 51.4 ng/ml) with no statistically significant difference (p > 0.05). Conclusion: Short-term daily folic acid supplementation over 8 weeks had a significant homocysteine reduction effect with no significant reduction in systolic and diastolic blood pressures of hypertensive subjects in Zaria, Nigeria. Hyperhomocysteinaemia could not be accounted for by suboptimal folate levels. Keywords: Hypertension, Homocysteine, Blood pressure, Folate, Placebo, Nigeria.

Sign in / Sign up

Export Citation Format

Share Document